Back to Journals » OncoTargets and Therapy » Volume 13

Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma

Authors Wu X, Hou P, Qiu Y, Wang Q, Lu X

Received 23 April 2020

Accepted for publication 3 July 2020

Published 31 July 2020 Volume 2020:13 Pages 7531—7543

DOI https://doi.org/10.2147/OTT.S257050

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Leo Jen-Liang Su


Xuechao Wu,* Peng Hou,* Yun Qiu, Qing Wang, Xiaojie Lu

Department of Neurosurgery, The Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University, Wuxi, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaojie Lu
Department of Neurosurgery, The Affiliated Wuxi, No.2 People’s Hospital of Nanjing Medical University, Wuxi, People’s Republic of China
Email luxiaojiewuxi@163.com

Purpose: Long non-coding RNA DGCR5 plays different roles in different types of cancer. The purpose of this study was to investigate the clinicopathological features, potential biological functions and prognostic significance of DGCR5 in glioma in a large-scale study.
Materials and Methods: A total of 697 RNA-seq data from The Cancer Genome Atlas (TCGA) and 301 mRNA microarray data from Chinese Glioma Genome Atlas (CGGA) were enrolled in this study. R language was used as the main tool for statistical analysis and graphical work.
Results: DGCR5 showed a negative correlation with the WHO grade of malignancy in glioma. Specifically, DGCR5 expression was significantly decreased in GBM and IDH wild-type glioma. Gene ontology analysis showed that DGCR5 was predominantly enriched in immune-related biological processes. Additionally, DGCR5 showed a significant correlation with stromal and immune cell populations, inflammatory activities and immune checkpoints. Clinically, patients with low-expression level of DGCR5 exhibited a worse overall survival.
Conclusion: DGCR5 expression is downregulated in glioma, and low DGCR5 independently predicts worse prognosis in glioma patients. Moreover, DGCR5 is significantly associated with immune response and immune infiltration. These findings suggest that DGCR5 is a promising immunotherapy target and a novel prognostic biomarker for glioma.

Keywords: DGCR5, immune infiltration, immune checkpoint, prognostic biomarker, glioma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]